Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma | MicrobiomeTrials← Back to trialsNCT06318286
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-03-13Est. Completion: 2026-06-30
Enrollment target: 25 participants Locations- Hyogo Medical University Hospital, Nishinomiya, Hyōgo, Japan
Other microbiome trials you might be interested in
Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustom…
Santa Rosa, United StatesEst. completion Nov 16, 2028
NSCLC AdenocarcinomaGastroesophageal Cancer (GC)Gastric AdenocarcinomaAdenocarcinoma of EsophagusSquamous Cell Car. - EsophagusUrothelial Carcinoma (UC)Bladder CancerMesothelioma
Pleural Mesothelioma
Peritoneal Mesothelioma
Non-Small Cell Lung Cancer NSCLC
Pancreatic Cancer
Biliary Tract Carcinoma
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherap…
Orlando, United StatesEst. completion Apr 30, 2028